| Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? | |
| | |
MedLine Citation:
|
PMID: 20143458 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In our examination of the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD), non-obese NAFLD patients without insulin resistance presented a characteristic pattern of dietary intake. Dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Namely, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. Therefore, the control of dietary cholesterol intake may lead to an improvement in NAFLD, and the NPC1L1 inhibitor ezetimibe might be a promising treatment for NAFLD. We review one pathogenic aspect of lipid metabolism dysregulation in NAFLD and survey new strategies for NAFLD treatment based on the modification of cholesterol metabolism. |
| | |
Authors:
|
Munechika Enjoji; Makoto Nakamuta |
Related Documents
:
|
7536138 - Early postoperative enteral nutrition with arginine-omega-3 fatty acids and ribonucleic... 11820238 - Energy and nutrient intake of patients in acute care. 2123908 - Electrophysiologic effects of isoproterenol in patients with atrioventricular reentrant... 16001098 - Superoxide dismutase and myeloperoxidase activities in polymorphonuclear leukocytes in ... 18370798 - Diet and the metabolic syndrome. 18789668 - Impaired translation initiation activation and reduced protein synthesis in weaned pigl... |
Publication Detail:
|
Type: Editorial; Review |
Journal Detail:
|
Title: World journal of gastroenterology : WJG Volume: 16 ISSN: 1007-9327 ISO Abbreviation: World J. Gastroenterol. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-09 Completed Date: 2010-05-04 Revised Date: 2010-09-28 |
Medline Journal Info:
|
Nlm Unique ID: 100883448 Medline TA: World J Gastroenterol Country: China |
Other Details:
|
Languages: eng Pagination: 800-3 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anticholesteremic Agents / therapeutic use* Azetidines / therapeutic use* Cholesterol, Dietary / adverse effects*, metabolism Fatty Liver / drug therapy*, etiology, metabolism Humans Liver / drug effects*, metabolism Membrane Proteins / antagonists & inhibitors, metabolism Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Azetidines; 0/Cholesterol, Dietary; 0/Membrane Proteins; 0/NPC1L1 protein, human; 163222-33-1/ezetimibe |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ontogeny, growth and development of the small intestine: Understanding pediatric gastroenterology.
Next Document: Current indications and role of surgery in the management of sigmoid diverticulitis.